On June 5, 2023, Oragenics, Inc. announced the award of a grant from CQDM, a Canadian bioresearch consortium, for the collaborative development of a variant-agnostic COVID-19 protein subunit vaccine candidate. The project is a collaboration with the National Research Council of Canada and Inspirevax. The grant funding is awarded through SynergiQC, a Quebec-based funding program for biopharmaceutical research created by CQDM.

SynergiQC is designed to promote academic-based industrial research in the biopharmaceutical field that will generate economic benefits across Quebec. CQDM extends its funding capacity to the development of biopharmaceutical products with high industrial and commercial value, such as more competitive molecules and other technologies.